Business
Annual Report and Accounts and date of AGM
Genedrive PLC has announced that its 2025 Annual Report and Accounts are now available on its website, with hard copies and the Notice of the 2025 Annual General Meeting to be posted to shareholders around December 8, 2025. The company's AGM is scheduled for December 31, 2025, at 10 am. This announcement primarily concerns corporate governance and shareholder communication, with no immediate financial performance data provided. Disclaimer*
About this update from Genedrive Plc
[{"type":"text","content":"\n\n \ngenedrive plc\n(\"genedrive\" or the \"Company\")\n \nAnnual Report and Accounts and date of AGM\n \ngenedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that its 2025 Annual Report and Accounts are now available on the Company's website https://investors.genedrive.com/reports-presentations-documents. The Notice of the 2025 Annual General Meeting (\"AGM\") and hard copies of the 2025 Annual Report and Accounts will be posted to shareholders on or around 8 December 2025.\n \nThe Company's AGM will be held at 10am on 31 December 2025 at 46 Grafton Street, Manchester M13 9XX.\n \nFor further details please contact:\n \n\n\n\n\ngenedrive plc\n\n\n+44 (0)161 989 0245\n\n\n\n\nGino Miele: CEO / Russ Shaw: CFO\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeel Hunt LLP (Nominated Adviser and Broker)\n\n\n+44 (0)20 7418 8900\n\n\n\n\nJames Steel\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Ltd (Media & Investor Relations)\n\n\n+44 (0)20 7933 8780 or [email protected]\n\n\n\n\nAnna Dunphy\n\n\n+44 (0)7876 741 001\n\n\n\n\n \nAbout genedrive plc (http://www.genedrive.com)\n \ngenedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ...